
Pharmaceutical Executive-01-01-2005


Pharmaceutical Executive
Citing cherry-picked patients, unrealistic dosing, and placebo control, payers will increasingly require that the proof for payment of drugs must come from head-to-head trials.

Pharmaceutical Executive
Heading the WHO list are pandemic influenza and antibiotic-resistant bacterial infections. Together the two could kill millions.
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
5